Tests CCS1477 (inobrodib) alone or with other drugs in blood cancers
Tests CCS1477 (inobrodib) in adults with advanced blood cancers, including leukemia and lymphoma.
Plain-language title generated from the registry record
Registry title: Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Key facts
- Where
- Atlanta, Bethesda, Indianapolis, Omaha, and Philadelphia, United StatesSee the 6 sites
- Phase
- Phase 1/2
Where in United States
- Emory Winship Cancer InstituteAtlanta, United StatesTaking people
- The Center for Cancer and Blood Disorders (CCBD)Bethesda, United StatesTaking people
- Community Health NetworkIndianapolis, United StatesTaking people
- Nebraska Cancer SpecialistsOmaha, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- Penn Medicine - Abramson Cancer Center PerelmanPhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CellCentric Ltd.
- Trial code
- NCT04068597
- Record updated
- 24 June 2026
- Original description
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.Read full original descriptionShow less
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Inclusion: Provision of consent; ECOG performance status 0-2; Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML); Must have previously received standard therapy; Adequate organ function.
Exclusion: Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose; Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment; Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment; Patients should discontinue statins prior to starting study treatment; Any unresolved reversible toxicities from prior therapy >CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy); Any evidence of severe or uncontrolled systemic diseases; Any known uncontrolled inter-current illness; Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment; CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment; QTcF prolongation (> 470 msec).